38 results about "E6 protein" patented technology

The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

The present invention relates to in vitro methods of screening human subjects for the presence of human papillomavirus (HPV) which exhibits loss of regulation of E6 / E7 mRNA expression and loss of replication and / or expression of a stabilized pre-mRNA encoding full length E6 protein. In particular, the invention provides in vitro methods of screening for persistent cell abnormalities or persistent CIN III lesions, cancer in situ or high-grade squamous intraepithelial lesions (HSIL). The methods are useful in the context of cervical cancer screening.

The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population.

The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population.

The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.

The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains.

The nucleic acid sequence provided by the present invention includes a 1:1 HPV16-AVLS1 sequence and an HPV16-AVLC1 sequence; and a 1:1 HPV18-AVLS1 sequence and an HPV18-AVLC1 sequence; the sequence AVLS1 and the sequence AVLC1 respectively include two tandem E6 proteins , two L1 short peptides, two L2 short peptides, two tandem E7 proteins, a PADRE sequence and an adjuvant sequence; the N-terminal of the sequence AVLS1 has a mouse IgK secretory peptide sequence; the N-terminal of the sequence AVLC1 has a pan prime sequence. The nucleic acid sequence provided by the invention can not only induce high-titer anti-E6 / E7 antibodies, but also induce high-level functional cellular immunity, showing excellent effects of preventing and treating HPV-related tumors.

The invention relates to application of Eu-containing polyoxometalate in the in-vitro assay of the early pathogenic protein E6 of human papillomavirus, which belongs to the technical field of assaying the early pathogenic protein E6 of human papillomavirus by means of polyoxometalate. The invention utilizes the strong recognition interaction between basic amino acid-rich small peptides on EuW10 and HPV E6 proteins to assay the HPV E6 protein. A research discovers that the E6 small peptide and protein can be assembled with EuW10 into spheres to promote the remarkable enhancement of fluorescence. The invention is the first example of utilizing polyoxometalate for in-vitro E6 protein assay. The polyoxometalate EuW10 synthesis method utilized by the invention is simple and easy to obtain. The assay method disclosed by the invention has the advantages of high assay speed, simplicity and convenience in operation, simple system, stable signals and high sensitivity, and does not need any pretreatment and a complex assay instrument. Through the invention, the application of polyoxometalate as a biological probe is expanded, which is of a great significance to the pre-cancer early assay of cervical cancer.

The present invention relates to in vitro methods of screening human subjects for the presence of human papillomavirus (HPV) which exhibits loss of regulation of E6 / E7 mRNA expression and loss of replication and / or expression of a stabilized pre-mRNA encoding full length E6 protein. In particular, the invention provides in vitro methods of screening for persistent transforming HPV infection equivalent to persistent cell abnormalities or persistent CIN III lesions, cancer in situ or high-grade squamous intraepithelial lesions (HSIL). The methods are useful in the context of cervical cancer screening.

The invention provides a gene for encoding HPV (human papilloma virus) 6-type L2N120E7E6 fusion protein, expression vectors, a method, a bacteria strain and an application. The invention is characterized in that prokaryotic expression vectors are utilized to fuse HPV 6-type L2N-end 120 amino acids, E7 proteins and E6 proteins, and constructing the encoded gene according to the amino acid of the fusion protein. In the invention, the gene for encoding the HPV 6-type L2N120E7E6 fusion proteins is successfully designed and the expression vectors and the transformation bacteria strain of the high-expression HPV 6-type L2N120E7E6 fusion proteins are successfully constructed; and in the fusion proteins, the immunogenicity is strong, the immunoreaction of specific T cells can be induced, the tumor forming time of mice can be obviously delayed, and the growth of the tumors of 20% mice is completely restrained. The invention can be used for preventing and treating HPV 6-type infection and relevant diseases, such as genital wart.

This invention relates to the minimal motif of an epitope on the E6 protein from human papilloma virus (HPV), and this minimal motif of the epitope induces a monoclonal antibody having cross-reactivity with some homologous proteins of HPVs. The inventors are the first to identify a fine antigenic epitope only existing conservatively on the E6 proteins of high risk HPV16, 33, 52 or 58). Therefore, the peptides comprising this epitope can be used to prepare immunogen or serological detection antigen against the HPV E6 proteins, or to prepare specific universal antibodies for a variety of high-risk / carcinogenic HPVs.

The invention provides a human papillomavirus (HPV) type 18 L2NE7E6 fusion protein gene, expression vector, method, bacterial strain and application highly expressed in Escherichia coli. In the present invention, the amino acid sequences of L2N protein, E7 protein and E6 protein at the 11-200th amino acid position of HPV18 L2 protein are fused, and a codon-optimized gene suitable for expression in Escherichia coli is designed, which is inserted into the prokaryotic expression vector pET9a to obtain pET9a- The expression level of HPV18L2NE7E6 expression vector and its transformed strains accounted for 50% of the whole bacteria. The purified fusion protein was immunized to mice, and the antibodies produced could neutralize HPV18 pseudoviruses, generate specific T cell immune responses, and significantly delay small At the time of mouse tumor formation, 20% of the mouse tumor growth was completely inhibited. The invention can be used for the research and development of vaccines for preventing and treating HPV18 infection and related diseases.

The invention discloses a nano-antibody capable of specifically combining HPVL6-E6 protein as well as a coding sequence, a preparation method and application thereof, an antibody VHH chain comprises aframework region and a complementarity determining region; the framework region comprises the following four amino acid sequences: FR1. SEQ ID NO: 1, FR2, SEQ ID NO: 3, FR3, SEQ ID NO: 5, FR4 and SEQID NO: 7; the complementarity determining region comprises the following three amino acid sequences: CDR1, SEQ ID NO: CDR2, SEQ ID NO: 4, CDR3, SEQ ID NO: 6. Compared with the prior art, the advantages are as follows: the nano-antibody capable of specifically binding to the HPV16-E6 protein has high specificity and high detection sensitivity; and the antibody can be efficiently expressed in escherichia coli, so that a foundation is provided for the mass production of a subsequent immune reagent and a tumor drug composition.